Sulfadoxine
drugOn this page
Also known as FanasulfJ21.373JNSC-759319RO-44393SulfadoxinSulfadoxinaSulfadoxine component of fansidarSulfadoxinumSulphadoxineSulforthamidineSulphormethoxineWR-4073SID11112518SID56463175SID144204074SID174006935SID170464751
Summary
Sulfadoxine (CHEMBL1539) is an approved small-molecule antibacterial drug; indicated across 8 conditions including malaria and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 8 conditions
- Clinical trials: 29
- Chemistry: 310.33 Da · C12H14N4O4S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1539 |
| Name | Sulfadoxine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 17134 |
| ChEBI | CHEBI:9329 |
| Molecular formula | C12H14N4O4S |
| Molecular weight | 310.33 |
| InChIKey | PJSFRIWCGOHTNF-UHFFFAOYSA-N |
SMILES: COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N
IUPAC name: 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
ChEBI definition: A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.
Pharmacological roles (ChEBI): antibacterial drug, antimalarial.
Also known as: Fanasulf, J21.373J, NSC-759319, RO-44393, Sulfadoxin, Sulfadoxina, Sulfadoxine, Sulfadoxine component of fansidar, Sulfadoxinum, Sulphadoxine, Sulforthamidine, Sulphormethoxine
Patent coverage: 3,291 distinct patent families (12,444 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,360 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| Plasmodium falciparum hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase | 7.14 |
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Estrogen receptor.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| malaria | 3 | MONDO:0005136 | EFO:0001068 |
| anemia | 3 | MONDO:0002280 | EFO:0004272 |
| Plasmodium falciparum malaria | 3 | MONDO:0005920 | EFO:0007444 |
| Plasmodium vivax malaria | 3 | MONDO:0005921 | EFO:0007445 |
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000764 |
| pneumocystosis | 3 | MONDO:0019121 | EFO:0007448 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 29.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 10 |
| Not specified | 9 |
| PHASE3 | 8 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00125489 | PHASE4 | COMPLETED | CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi |
| NCT00164255 | PHASE4 | COMPLETED | Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy |
| NCT00168948 | PHASE4 | UNKNOWN | Intermittent Antimalaria Treatment With SP in African Children |
| NCT00206739 | PHASE4 | COMPLETED | Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants |
| NCT00376155 | PHASE4 | COMPLETED | Comparison of Two Strategies for the Delivery of IPTc |
| NCT00453856 | PHASE4 | TERMINATED | Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children |
| NCT03178643 | PHASE4 | COMPLETED | Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) |
| NCT05478954 | PHASE4 | UNKNOWN | Chemoprevention Efficacy Study in Burkina Faso |
| NCT05980156 | PHASE4 | COMPLETED | Comparing Chemoprevention Drugs for School-based Malaria Control |
| NCT06337253 | PHASE4 | UNKNOWN | Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique |
| NCT00000727 | PHASE3 | COMPLETED | A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT) |
| NCT00132548 | PHASE3 | COMPLETED | A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children |
| NCT00132561 | PHASE2/PHASE3 | COMPLETED | A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children |
| NCT00299247 | PHASE3 | WITHDRAWN | SP Resistance and Falciparum Malaria Transmission |
| NCT00361114 | PHASE3 | TERMINATED | IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria. |
| NCT00399074 | PHASE3 | COMPLETED | Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia |
| NCT00646126 | PHASE3 | COMPLETED | Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission |
| NCT04783051 | PHASE3 | COMPLETED | Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) |
| NCT05471544 | PHASE3 | UNKNOWN | Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan |
| NCT05497063 | PHASE1 | UNKNOWN | Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions |
| NCT05856357 | Not specified | ACTIVE_NOT_RECRUITING | Perennial Malaria Chemoprevention (PMC) in Côte D’Ivoire |
| NCT05889052 | Not specified | ACTIVE_NOT_RECRUITING | Perennial Malaria Chemoprevention (PMC) in Cameroon |
| NCT05949190 | Not specified | ACTIVE_NOT_RECRUITING | Improving Cognition and Gestational Duration With Targeted Nutrition |
| NCT06869850 | Not specified | RECRUITING | Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition |
| NCT00766662 | Not specified | COMPLETED | Intermittent Preventive Treatment in Infant in Mali |
| NCT03454048 | Not specified | COMPLETED | Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 |
| NCT03944317 | Not specified | UNKNOWN | Azithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Malaria Prevention in Pregnant Women (IPT-AZ/IPT-SP) |
| NCT05354258 | Not specified | UNKNOWN | Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children |
| NCT06002438 | Not specified | COMPLETED | Eggs for Gut Health |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).